Lenograstim: Clinical Trials

7 trials of Lenograstim, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 1 terminated, 1 unknown. 7 Phase 2, 3 Phase 3, 2 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 27Completed 5, Terminated 1, Unknown 1
Phase 33Completed 2, Terminated 1
Phase 12Completed 1, Unknown 1

Follow Lenograstim: new trials by email Literature Review of Lenograstim trials Research Report on Lenograstim

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Phase II Study Evaluating Intravenous Melphalan With Autologous Whole Blood Stem Cell Transplantation Over Three Cycles In Patients With Castration-Resistant Prostate Cancer (MEL-CAP)
Melphalan, Lenograstim - Castrate Resistant Prostate Cancer
Phase 2 / Phase 3TerminatedBarts & The London NHS Trust292013-01-012023-04-19
Trial Evaluating Induction Therapy With Idarubicin and Etoposide Plus Sequential or Concurrent Azacitidine and Maintenance Therapy With Azacitidine
Cytarabine, Idarubicin, Etoposide - Acute Myeloid Leukemia (AML)
Phase 2CompletedUniversity of Ulm2772010-11-012020-12-31
Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy
granulocyte colony stimulating factor (GCSF), bone marrow mononuclear cells - Dilated Cardiomyopathy
Phase 2CompletedBarts & The London NHS Trust602010-08-012013-11-15
Sitagliptin Plus Granulocyte-colony Stimulating Factor in Acute Myocardial Infarction
Lenograstim (GRANOCYTE)=GCSF, Sitagliptin (Januvia), Sodium Chloride (NaCl) 0.9 % - Acute Myocardial Infarction
Phase 2 / Phase 3CompletedLudwig-Maximilians - University of Munich1742008-03-012022-08-25
Gemcitabine, Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Progressive or Relapsed Metastatic Germ Cell Tumors
filgrastim, lenograstim, pegfilgrastim - Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor
Phase 1 / Phase 2UnknownUniversity of Southampton232006-11-012013-01-23
Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL
Bortezomib, Cyclophosphamide, Doxorubicin - Lymphoma, Large-Cell, Diffuse, Lymphoma, B-Cell
Phase 1 / Phase 2CompletedAsan Medical Center492006-09-012013-03-15
Predictive Value of the "Cytocapacity Test" Patients With Lymphoproliferative Diseases and High-dose Therapy
lenograstim - Hodgkin's Disease, Non-Hodgkin Lymphomas
Phase 2 / Phase 3CompletedWiSP Wissenschaftlicher Service Pharma GmbH1692003-05-012010-03-11

Conditions studied

Cardiomyopathy, Dilated (1)  ·  Central Nervous System Neoplasms (1)  ·  Endodermal Sinus Tumor (1)  ·  Hodgkin Disease (1)  ·  Leukemia, Myeloid, Acute (1)  ·  Lymphoma, B-Cell (1)  ·  Lymphoma, Large B-Cell, Diffuse (1)  ·  Multiple Myeloma (1)  ·  Myocardial Infarction (1)  ·  Ovarian Neoplasms (1)  ·  Seminoma (1)  ·  Testicular Germ Cell Tumor (1)  ·  Testicular Neoplasms (1)

Sponsors

Barts & The London NHS Trust (2)  ·  Asan Medical Center (1)  ·  Ludwig-Maximilians - University of Munich (1)  ·  University of Southampton (1)  ·  University of Ulm (1)  ·  WiSP Wissenschaftlicher Service Pharma GmbH (1)

Countries

United Kingdom (3)  ·  Germany (2)  ·  Austria (1)  ·  South Korea (1)

Top investigators

Anthony Mathur, MD FRCP FESC (1)  ·  Cheolwon Suh, M.D.,Ph.D. (1)  ·  G. Mead, MD (1)  ·  Jonathan Shamash, MD FRCP (1)  ·  Richard F Schlenk, MD (1)  ·  Wolfgang M Franz, Prof. Dr. (1)

Results publications

PMID 21163927, PMID 26709136, PMID 37885041

NIH funding

2009 (1)